Robert Orr, U.S. Food and Drug Administration. fda.gov. October 25, 2023.
The 2023 FDA presentation repeats 75F40120C00176 as an FDA/OMHHE collaboration studying COVID-19 illness in diverse populations. It provides a later official account of the same funding relationship described in 2022, rather than a new independent study or award. Nolan’s connection comes from the separate MaxFuse acknowledgement; no classified UAP access is reported.
◧ Partial root native PDF text and selected layout review
Robert Orr, U.S. Food and Drug Administration. fda.gov. December 6, 2022.
Robert Orr’s FDA presentation publicly describes a 2017 modification of contract HHSF223201610018C and links 75F40120C00176 to a collaboration studying COVID-19 illness in diverse populations. These identifiers match contracts acknowledged for Nolan in MaxFuse. The slides document agency statements about public research funding; they do not name Nolan or establish secret invitations or UAP access.
◧ Partial root native PDF text and selected layout review
An FDA contract listing names Stanford University for 75F40120C00176, independently of the MaxFuse acknowledgement. The requirement concerns coronavirus research. Its wording differs from a later FDA presentation using the same identifier; the amendment or naming history remains unresolved. This supports a public institutional funding link, without establishing Nolan as the named principal investigator or a classified programme.
◧ Partial root native PDF text and selected layout review
A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach